Literature DB >> 1372185

Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes.

J F Mahoney1, M Urakaze, S Hall, R DeGasperi, H M Chang, E Sugiyama, C D Warren, M Borowitz, A Nicholson-Weller, W F Rosse.   

Abstract

To investigate the biosynthesis of the glycosylphosphatidylinositol (GPI) anchor in the granulocytes of paroxysmal nocturnal hemoglobinuria (PNH), the glycolipids of granulocytes from PNH patients and normal volunteers were biosynthetically labeled with [3H]mannose in the presence of tunicamycin. Extracted glycolipids were examined by thin-layer chromatography and compared with known biosynthetic intermediates. Normal granulocytes consistently showed [3H]mannose incorporation into the complete GPI core, several GPI biosynthetic intermediates, and dolichol phosphate mannose (DPM). The granulocytes of 10 patients with PNH that had no expression of CD55 and CD59 on greater than 95% of the cells were able to incorporate [3H]mannose into DPM, but were not able to incorporate detectable amounts into the complete GPI core. THus, PNH granulocytes do not synthesize detectable amounts of the complete GPI core and this defect likely accounts for the absence of GPI-linked membrane proteins on hematopoietic cells in this syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372185

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 2.  Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.

Authors:  E T Yeh; W F Rosse
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

3.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

4.  Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; M Bessler; P J Mason; W M Watkins; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

5.  Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.

Authors:  M Hatanaka; T Seya; M Matsumoto; T Hara; M Nonaka; N Inoue; J Takeda; A Shimizu
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

Review 6.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Authors:  Antonio M Risitano; Serena Marotta; Patrizia Ricci; Luana Marano; Camilla Frieri; Fabiana Cacace; Michela Sica; Austin Kulasekararaj; Rodrigo T Calado; Phillip Scheinberg; Rosario Notaro; Regis Peffault de Latour
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

7.  Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  M Takahashi; J Takeda; S Hirose; R Hyman; N Inoue; T Miyata; E Ueda; T Kitani; M E Medof; T Kinoshita
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

8.  Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going.

Authors:  Antonio M Risitano
Journal:  Transl Med UniSa       Date:  2014-02-04

Review 9.  How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.

Authors:  Antonio Maria Risitano; Régis Peffault de Latour
Journal:  Br J Haematol       Date:  2021-08-05       Impact factor: 8.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.